Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

N. Lynn Henry, James M. Rae, Lang Li, Faouzi Azzouz, Todd Skaar, Zeruesenay Desta, Matthew J. Sikora, Santosh Philips, Anne T. Nguyen, Anna Maria Storniolo, Daniel F. Hayes, David A. Flockhart, Vered Stearns

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women initiating tamoxifen. We performed CYP2D6 genotyping using the AmpliChip CYP450 test and correlated inherited genetic polymorphisms in CYP2D6 and tamoxifen-induced hot flashes. Intermediate metabolizers had greater mean hot flash scores after 4 months of tamoxifen therapy (44.3) compared to poor metabolizers (20.6, P = 0.038) or extensive metabolizers (26.9, P = 0.011). At 4 months, we observed a trend toward fewer severe hot flashes in poor metabolizers compared to intermediate plus extensive metabolizers (P = 0.062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy.

Original languageEnglish
Pages (from-to)571-575
Number of pages5
JournalBreast Cancer Research and Treatment
Volume117
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Hot Flashes
Cytochrome P-450 CYP2D6
Tamoxifen
Genotype
Genetic Polymorphisms

Keywords

  • Breast cancer
  • CYP2D6
  • Genotype
  • Hot flash
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. / Lynn Henry, N.; Rae, James M.; Li, Lang; Azzouz, Faouzi; Skaar, Todd; Desta, Zeruesenay; Sikora, Matthew J.; Philips, Santosh; Nguyen, Anne T.; Storniolo, Anna Maria; Hayes, Daniel F.; Flockhart, David A.; Stearns, Vered.

In: Breast Cancer Research and Treatment, Vol. 117, No. 3, 2009, p. 571-575.

Research output: Contribution to journalArticle

Lynn Henry, N, Rae, JM, Li, L, Azzouz, F, Skaar, T, Desta, Z, Sikora, MJ, Philips, S, Nguyen, AT, Storniolo, AM, Hayes, DF, Flockhart, DA & Stearns, V 2009, 'Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort', Breast Cancer Research and Treatment, vol. 117, no. 3, pp. 571-575. https://doi.org/10.1007/s10549-009-0309-1
Lynn Henry, N. ; Rae, James M. ; Li, Lang ; Azzouz, Faouzi ; Skaar, Todd ; Desta, Zeruesenay ; Sikora, Matthew J. ; Philips, Santosh ; Nguyen, Anne T. ; Storniolo, Anna Maria ; Hayes, Daniel F. ; Flockhart, David A. ; Stearns, Vered. / Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. In: Breast Cancer Research and Treatment. 2009 ; Vol. 117, No. 3. pp. 571-575.
@article{9548caa384dc4309a3dc7084dbcd8e33,
title = "Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort",
abstract = "Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women initiating tamoxifen. We performed CYP2D6 genotyping using the AmpliChip CYP450 test and correlated inherited genetic polymorphisms in CYP2D6 and tamoxifen-induced hot flashes. Intermediate metabolizers had greater mean hot flash scores after 4 months of tamoxifen therapy (44.3) compared to poor metabolizers (20.6, P = 0.038) or extensive metabolizers (26.9, P = 0.011). At 4 months, we observed a trend toward fewer severe hot flashes in poor metabolizers compared to intermediate plus extensive metabolizers (P = 0.062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy.",
keywords = "Breast cancer, CYP2D6, Genotype, Hot flash, Tamoxifen",
author = "{Lynn Henry}, N. and Rae, {James M.} and Lang Li and Faouzi Azzouz and Todd Skaar and Zeruesenay Desta and Sikora, {Matthew J.} and Santosh Philips and Nguyen, {Anne T.} and Storniolo, {Anna Maria} and Hayes, {Daniel F.} and Flockhart, {David A.} and Vered Stearns",
year = "2009",
doi = "10.1007/s10549-009-0309-1",
language = "English",
volume = "117",
pages = "571--575",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

AU - Lynn Henry, N.

AU - Rae, James M.

AU - Li, Lang

AU - Azzouz, Faouzi

AU - Skaar, Todd

AU - Desta, Zeruesenay

AU - Sikora, Matthew J.

AU - Philips, Santosh

AU - Nguyen, Anne T.

AU - Storniolo, Anna Maria

AU - Hayes, Daniel F.

AU - Flockhart, David A.

AU - Stearns, Vered

PY - 2009

Y1 - 2009

N2 - Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women initiating tamoxifen. We performed CYP2D6 genotyping using the AmpliChip CYP450 test and correlated inherited genetic polymorphisms in CYP2D6 and tamoxifen-induced hot flashes. Intermediate metabolizers had greater mean hot flash scores after 4 months of tamoxifen therapy (44.3) compared to poor metabolizers (20.6, P = 0.038) or extensive metabolizers (26.9, P = 0.011). At 4 months, we observed a trend toward fewer severe hot flashes in poor metabolizers compared to intermediate plus extensive metabolizers (P = 0.062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy.

AB - Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women initiating tamoxifen. We performed CYP2D6 genotyping using the AmpliChip CYP450 test and correlated inherited genetic polymorphisms in CYP2D6 and tamoxifen-induced hot flashes. Intermediate metabolizers had greater mean hot flash scores after 4 months of tamoxifen therapy (44.3) compared to poor metabolizers (20.6, P = 0.038) or extensive metabolizers (26.9, P = 0.011). At 4 months, we observed a trend toward fewer severe hot flashes in poor metabolizers compared to intermediate plus extensive metabolizers (P = 0.062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy.

KW - Breast cancer

KW - CYP2D6

KW - Genotype

KW - Hot flash

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=70349575970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349575970&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0309-1

DO - 10.1007/s10549-009-0309-1

M3 - Article

VL - 117

SP - 571

EP - 575

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -